Guggenheim began coverage on shares of Grail (NASDAQ:GRAL – Free Report) in a research report report published on Thursday morning, Marketbeat reports. The brokerage issued a neutral rating on the stock.
Grail Stock Up 3.9 %
Shares of NASDAQ:GRAL opened at $14.76 on Thursday. The firm’s fifty day moving average is $14.19. Grail has a 1-year low of $12.33 and a 1-year high of $23.36.
Grail (NASDAQ:GRAL – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($5.30) earnings per share (EPS) for the quarter. The business had revenue of $31.97 million for the quarter.
Insiders Place Their Bets
About Grail
GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
See Also
- Five stocks we like better than Grail
- What is the Australian Securities Exchange (ASX)
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.